Lin Wu

机构：Chongqing Normal University, Shenzhen Bay Laboratory, Xi'an Medical University, Shanghai Changning Mental Health Center, East China Normal University · ORCID：0000-0003-3166-0530

发表论文 129 篇 · 总被引 1744 次 · h-index 23

代表论文

• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer (2024 · Med · 被引 45)
• Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations (2024 · The Innovation · 被引 13)
• Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH) (2025 · International Journal of Radiation Oncology*Biology*Physics · 被引 8)
• HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer (2025 · Journal of Translational Medicine · 被引 8)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)